본문으로 건너뛰기
Stock Expert AI

WisdomTree BioRevolution Fund (WDNA) Holdings

이 페이지는 영어 원문에서 AI로 기계 번역되었습니다. 영어 버전이 기준입니다. 영어 버전 읽기

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

빠른 답변

WisdomTree BioRevolution Fund (WDNA) has a last stored price of $23.23, as of the Oct 26, 2026 trading session. It has a 0.45% expense ratio and $2M in assets under management.

Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Moderna Inc (MRNA) at 4.46%, and the largest sector allocation is Healthcare at 91.9%.

WisdomTree BioRevolution Fund (WDNA) ETF — Price, Holdings & Analysis

ETF 개요

WDNA aims to capture the growth potential of companies at the forefront of the bio-revolution, focusing on those expected to be significantly impacted by advancements in genetics and biotechnology. The fund tracks the BioRevolution Index, providing exposure to companies listed globally. WDNA utilizes a representative sampling strategy, meaning it invests in a carefully selected subset of the index's constituents that collectively mirror the risk, return, and other characteristics of the entire index. This approach allows WDNA to efficiently track the index while managing costs. The fund's top holdings include companies like Moderna Inc (4.46%), Johnson & Johnson (2.97%), and Eli Lilly and Co (2.83%). WDNA is heavily concentrated in the Healthcare sector (91.9%), with smaller allocations to Basic Materials (5.0%) and Consumer Defensive (3.1%). The fund is non-diversified, indicating a concentrated investment approach within the bio-revolution theme, making it suitable for investors seeking targeted exposure to this specific area.

위험 지표

WDNA's concentration in the Healthcare sector (91.9%) exposes it to sector-specific risks, meaning that the fund's performance is closely tied to the performance of the healthcare industry and any adverse events affecting this sector could significantly impact the fund's value. The fund's non-diversified status further amplifies concentration risk, as a smaller number of holdings contribute a larger portion of the fund's overall performance. As of 2026-03-15, WDNA has a beta of 1.69, indicating higher volatility compared to the broader market. The expense ratio of 0.45% will create a drag on returns, especially in periods of lower performance. Their risk tolerance and investment horizon may be worth researching before investing in WDNA, given its sector concentration, non-diversified nature, and relatively high beta.
  • 베타: 1.69

운용보수율

0.45%

WDNA은(는) 무엇을 보유하고 있나요?

보유 종목비중
Moderna Inc (MRNA)4.46%
Johnson & Johnson (JNJ)2.97%
Eli Lilly and Co (LLY)2.83%
Structure Therapeutics Inc ADR (GPCR)2.69%
Stoke Therapeutics Inc (STOK)2.64%
Pfizer Inc (PFE)2.50%
Natera Inc (NTRA)2.44%
Amgen Inc (AMGN)2.43%
BioNTech SE ADR (BNTX)2.41%
AstraZeneca PLC (AZN.L)2.24%

이 펀드 데이터는 45일 이상 지났습니다. 최신 보유 종목은 발행사에서 확인하세요.

펀드는 어떻게 배분되어 있나요?

섹터비중
헬스케어91.9%
기초 소재5.0%
필수소비재3.1%
국가비중
미국78.9%
덴마크4.8%
영국4.6%
스위스3.9%
독일3.8%
네덜란드2.0%
일본1.1%
벨기에0.5%
호주0.3%
기타0.1%

배당수익률

0.00%

질문 및 답변

What is WDNA and what does it track?

The WisdomTree BioRevolution Fund (WDNA) is a sector equity ETF that seeks to track the investment results of the BioRevolution Index.

This index is designed to provide exposure to equity securities of exchange-listed companies globally that are expected to be significantly transformed by advancements in genetics and biotechnology.

What is the expense ratio for WDNA?

The expense ratio for WDNA is 0.45%. This means that for every $10,000 invested in the fund, $45 is deducted annually to cover operating expenses.

While 0.45% is not extremely high, it's important to consider this cost as it will impact the overall return of the investment. When evaluating WDNA, investors should compare its expense ratio to those of similar sector equity ETFs to determine if it offers competitive value.

What are the top holdings in WDNA?

As of 2026-03-15, the top holdings in WDNA include Moderna Inc (4.46%), Johnson & Johnson (2.97%), and Eli Lilly and Co (2.83%).

These companies represent a significant portion of the fund's overall portfolio and reflect its focus on the bio-revolution theme. Other notable holdings include Structure Therapeutics Inc ADR (2.69%) and Stoke Therapeutics Inc (2.64%).

Is WDNA a good long-term investment?

Whether WDNA is a suitable long-term investment depends on an individual investor's risk tolerance, investment goals, and time horizon. WDNA offers targeted exposure to the bio-revolution theme, which may present long-term growth opportunities.

However, the fund's concentration in the Healthcare sector (91.9%) and its non-diversified nature introduce sector-specific risks.

How does WDNA compare to similar ETFs?

WDNA distinguishes itself through its specific focus on companies expected to be significantly transformed by advancements in genetics and biotechnology. While other healthcare or biotechnology ETFs may offer broader exposure, WDNA provides a more targeted approach to the 'bio-revolution' theme.

Its expense ratio is 0.45%. As of 2026-03-15, WDNA has $0.00B in assets under management.

Does WDNA pay dividends?

As of 2026-03-15, the WisdomTree BioRevolution Fund (WDNA) has a dividend yield of 0.00%. This indicates that the fund does not currently distribute dividends to its shareholders.

Investors seeking income-generating investments may want to consider other ETFs with a history of dividend payments.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.

이 페이지는 기계가 작성했으며, 페이지별 사람 검수는 거치지 않았습니다. 편집 관리는 체계 차원에서 이루어집니다: 규칙과 출처를 점검하며, 개별 페이지는 점검하지 않습니다.